LONDON--(BUSINESS WIRE)--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon’s science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research. The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Ha...PARIS--(BUSINESS WIRE)--Regulatory News : TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Nombre d'actions composant le capital Nombre de droits de vote Théoriques (1) Exerçables (2) 30 juin 2025 2 281 206 254 2 281 206 254 2 203 252 281 (1) Conformément à l’article 223-11 du règlement général de l’Autorité des Marchés Financiers, ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote. (2) N...PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights Theoretical (1) Exercisable (2) June 30, 2025 2,281,206,254 2,281,206,254 2,203,252,281 (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended. (2) Total number of exercisable voting rig...TORONTO--(BUSINESS WIRE)--Striking workers from the Villa Colombo Supportive Housing Unit are thankful that their struggle isn’t going unnoticed by the wider labour movement. These personal care workers are members of CUPE 5525 and have been on the picket line since May 28th outside the care residences, operated by Villa Colombo Home for the Aged and Villa Charities at Dufferin and Lawrence. The Society of United Professionals added their union to the growing list of supportive organizations, u...PARIS--(BUSINESS WIRE)--Regulatory News: Tikehau Capital (Paris:TKO) annonce que Esta Investments Pte. Ltd. ("Esta Investments", véhicule d'investissement contrôlé par le fonds souverain singapourien Temasek) l'a informé ce jour avoir franchi à la hausse le seuil de 5% de son capital et de ses droits de vote. Ce franchissement de seuil résulte d'un échange d'actions Tikehau Capital Advisors contre des actions Tikehau Capital réalisé entre Esta Investments et Tikehau Capital Advisors, actionnair...PARIS--(BUSINESS WIRE)--Regulatory News: Tikehau Capital (Paris:TKO) announces that Esta Investments Pte. Ltd. ("Esta Investments", an investment vehicle controlled by Singapore’s sovereign wealth fund Temasek) has informed the firm today that it has crossed the 5% threshold of its share capital and voting rights. This threshold crossing results from a share swap carried out between Esta Investments and Tikehau Capital Advisors, the controlling shareholder of Tikehau Capital, majority-owned by...LONDEN--(BUSINESS WIRE)--SCENTMATIC Inc., een leider in digitalisering van geuren, introduceerde KAORIUM, haar 'scent-to-language' systeem aangestuurd door AI, tijdens het THAMEEN Fragrance-evenement voor lancering van nieuwe producten. Dit belangrijke evenement vond plaats van 5 tot 11 juni 2025 in de afdelingswinkel van Selfridges in Londen, Verenigd Koninkrijk. Wereldwijde uitbreiding: KAORIUM vestigt haar aanwezigheid in de UK Europa is koploper in de wereldwijde parfummarkt, en naar verwac...PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX) Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total voting rights Total gross (1) Total net (2) June 30, 2025 34,931,012 44,381,814 44,060,935 (1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shar...PARIS--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX) Place de cotation : Euronext Paris, Compartiment C Code ISIN : FR0012616852 Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total brut (1) Total net (2) 30 juin 2025 34 931 012 44 381 814 44 060 935 (1) Le nombre de droits de vote bruts (ou droits de vote “théoriques”) sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l’AMF...PARIS--(BUSINESS WIRE)--Regulatory News: Maurel & Prom (Paris:MAU): Under the liquidity contract entered into between ETABLISSEMENTS MAUREL ET PROM and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30 2025: - 156,395 shares - € 632,406.37 During the first half of 2025: - Number of executions on buy side on semester: 3,716 - Number of executions on sell side on semester: 3,688 - Traded volume on buy side on semester: 2,025,936 shares for € 10,521,869.58...


    LONDON--(BUSINESS WIRE)--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon’s science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research.
The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Haleon’s ambition to reach one billion more consumers by 2030, by strengthening its oral health R&D capabilities to put health in more hands globally. Set to become the R&D epicentre for Haleon’s oral health portfolio, the centre will be a dynamic hub for pioneering research, product innovation, commercial and supply chain excellence, and cross-functional collaboration.


Equipped with the latest technology and global expertise, the centre will feature a cutting-edge digital immersive room designed to unlock value at pace through real-time collaboration with Haleon’s manufacturing site in Levice.


At the heart of the building, the atrium will create a vibrant hub for teamwork and co-creation, bringing leading expertise together to develop solutions that address unmet oral health needs for consumers around the world.


Designed with sustainability at its core, the site has recently achieved a BREEAM® Outstanding rating, recognising its exceptional commitment to sustainability at Phase 1 in the design stage.


Franck Riot, Chief R&D Officer, Haleon, said: "We are excited to break ground on our Global Oral Health Innovation Centre - a major investment reflecting our commitment to advancing science and innovation. This powerhouse for oral health research will strengthen Haleon’s R&D capabilities and accelerate the development of cutting-edge solutions to meet the evolving oral health needs of consumers around the world.”


Chancellor of the Exchequer, Rachel Reeves MP, said: “This exciting milestone is another demonstration of the strength of the UK life sciences sector, a key pillar to our Industrial Strategy. Under this government Britain is open for business, and through our Plan for Change we’re delivering more investment, more jobs and more money in people’s pockets.”


UK Minister for Technology, Baroness Jones, said: “Haleon is breaking ground on a new centre that will place the UK at the forefront of innovation to improve everyone’s oral health - which we know is important to our wider health, and to children’s development. This centre, and the substantial investment behind it, is proof that the UK’s world-leading life sciences sector is the place to be to grow businesses and work on fresh ideas to transform healthcare. Leveraging these strengths will lead to the long-term economic growth that will help us deliver on our Plan for Change.”


Jayant Singh, Global Category Lead, Oral Health, Haleon, said: "With oral diseases affecting nearly half the world’s population, this marks an exciting step forward in our mission to put health in more hands for millions across the world. This centre will play a key role in harnessing the full potential of science and innovation across our oral health portfolio.”


About Haleon


Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.



Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

<article>
 <div id="bw-release-story" class="press-release ui-kit-press-release-content overflow-hidden bw-release-story ui-kit-press-release-body__story mt-6 lg:mt-10 font-oxygen text-base font-normal leading-[1.5em] lg:text-xl lg:leading-[1.6em]" style="overflow: hidden; margin-top: 1.5rem; font-family: 'Oxygen', sans-serif; font-size: 1rem; line-height: 1.5em;">
 
 LONDON--(<a href="https://www.businesswire.com" target="_blank" style="color: blue; text-decoration: underline;">BUSINESS WIRE</a>)--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon’s science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research.
 
 
 The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Haleon’s ambition to reach one billion more consumers by 2030, by strengthening its oral health R&D capabilities to put health in more hands globally. Set to become the R&D epicentre for Haleon’s oral health portfolio, the centre will be a dynamic hub for pioneering research, product innovation, commercial and supply chain excellence, and cross-functional collaboration.
 
 
 Equipped with the latest technology and global expertise, the centre will feature a cutting-edge digital immersive room designed to unlock value at pace through real-time collaboration with Haleon’s manufacturing site in Levice.
 
 
 At the heart of the building, the atrium will create a vibrant hub for teamwork and co-creation, bringing leading expertise together to develop solutions that address unmet oral health needs for consumers around the world.
 
 
 Designed with sustainability at its core, the site has recently achieved a BREEAM® Outstanding rating, recognising its exceptional commitment to sustainability at Phase 1 in the design stage.
 
 
 Franck Riot, Chief R&D Officer, Haleon, said: "We are excited to break ground on our Global Oral Health Innovation Centre - a major investment reflecting our commitment to advancing science and innovation. This powerhouse for oral health research will strengthen Haleon’s R&D capabilities and accelerate the development of cutting-edge solutions to meet the evolving oral health needs of consumers around the world.”
 
 
 Chancellor of the Exchequer, Rachel Reeves MP, said: “This exciting milestone is another demonstration of the strength of the UK life sciences sector, a key pillar to our Industrial Strategy. Under this government Britain is open for business, and through our Plan for Change we’re delivering more investment, more jobs and more money in people’s pockets.”
 
 
 UK Minister for Technology, Baroness Jones, said: “Haleon is breaking ground on a new centre that will place the UK at the forefront of innovation to improve everyone’s oral health - which we know is important to our wider health, and to children’s development. This centre, and the substantial investment behind it, is proof that the UK’s world-leading life sciences sector is the place to be to grow businesses and work on fresh ideas to transform healthcare. Leveraging these strengths will lead to the long-term economic growth that will help us deliver on our Plan for Change.”
 
 
 Jayant Singh, Global Category Lead, Oral Health, Haleon, said: "With oral diseases affecting nearly half the world’s population, this marks an exciting step forward in our mission to put health in more hands for millions across the world. This centre will play a key role in harnessing the full potential of science and innovation across our oral health portfolio.”
 
 
 About Haleon
 
 
 Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
 
 </div>
</article>

Haleon launched a Global Oral Health Innovation Centre in Surrey.
The centre aims to enhance R&D and accelerate product innovation.
It supports Haleon's goal to reach one billion consumers by 2030.
The facility features advanced technology and sustainability at its core.
The UK government supports this investment for economic growth.

Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News